Trials / Completed
CompletedNCT03669393
A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)
A Phase 2, Open-label, Multi-centre Study to Assess the Efficacy and Safety of Intravitreal THR-317 for the Treatment of Macular Telangiectasia Type 1 (MacTel 1)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- ThromboGenics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted to evaluate the safety of THR-317 when administered intravitreally and to assess the compound's efficacy in reducing central subfield thickness (CST) and improving best-corrected visual acuity (BCVA) in subjects with macular telangiectasia Type 1 (MacTel 1).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | THR-317 8mg | 3 intravitreal injections of THR-317 8mg, approximately 1 month apart |
Timeline
- Start date
- 2018-09-18
- Primary completion
- 2019-11-22
- Completion
- 2019-11-22
- First posted
- 2018-09-13
- Last updated
- 2020-09-02
Locations
3 sites across 2 countries: France, Switzerland
Source: ClinicalTrials.gov record NCT03669393. Inclusion in this directory is not an endorsement.